Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's Laboratories announces the launch of a generic version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg
in the U.S. Market."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (PH: +91-40-49002135) | PRANAV PRIMLANI pranav.primlani@drreddys.com (Ph: +91-9381905796) |
Laboratories announces the launch of a
generic version of Sapropterin Dihydrochloride
Powder for Oral Solution, 100 mg in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. April 7, 2021 - Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr.
Reddy's") today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic
equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S.
Food and Drug Administration (USFDA).
"We are pleased to launch this generic version of Sapropterin
Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bring affordable generic medicines to market
for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "At
the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare
Dr. Reddy's Sapropterin Dihydrochloride Powder for Oral Solution,
is available in 100 mg unit dose packets in a 30 count carton.
Please see the full prescribing information.
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd.
(BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the management's current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,
(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates,
persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks
and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi)
the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic
downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19),
and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including
those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."